Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Pegorgotein 2-methoxyethyl 3-aminocarbonylpropanoate

Synonyms: AC1MJ6LH, 155773-57-2, 2-methoxyethyl 4-amino-4-oxobutanoate

Muelleman, R.L. et al., Butterworth, J. et al., Young, B. et al., Muizelaar, J.P.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PEG-SOD

OBJECTIVE: To evaluate outcome of patients with severe closed head injury treated with pegorgotein, a scavenger of oxygen-derived free radicals [1].
Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial [1].
A randomized, blinded trial of the antioxidant pegorgotein: no reduction in neuropsychological deficits, inotropic drug support, or myocardial ischemia after coronary artery bypass surgery [2].
CONCLUSIONS: This study showed no positive influence of pegorgotein on the incidence of any of the findings and showed a trend toward an increased incidence of myocardial ischemia or infarction [2].

High impact information on PEG-SOD

These results indicate no significant treatment effect for pegorgotein on tissue survival in a rabbit frostbite injury model when administered immediately postinjury [3].

Analytical, diagnostic and therapeutic context of PEG-SOD

A control group received no pharmacologic therapy; the treatment group received 10,000 IU/kg pegorgotein intravenously immediately postinjury [3].
This study evaluated the efficacy of pegorgotein on frostbite tissue survival when administered prior to rewarming [3].
Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury [4].

References

Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. Young, B., Runge, J.W., Waxman, K.S., Harrington, T., Wilberger, J., Muizelaar, J.P., Boddy, A., Kupiec, J.W. JAMA (1996) [Pubmed]
A randomized, blinded trial of the antioxidant pegorgotein: no reduction in neuropsychological deficits, inotropic drug support, or myocardial ischemia after coronary artery bypass surgery. Butterworth, J., Legault, C., Stump, D.A., Coker, L., Hammon, J.W., Troost, B.T., Royster, R.L., Prough, D.S. J. Cardiothorac. Vasc. Anesth. (1999) [Pubmed]
The use of pegorgotein in the treatment of frostbite. Muelleman, R.L., Grandstaff, P.M., Robinson, W.A. Wilderness & environmental medicine. (1997) [Pubmed]
Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Muizelaar, J.P. Adv. Exp. Med. Biol. (1994) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.